Analyst Consensus ?
ConsensusHold40 ratings
Bullish2152.5%
Neutral1640.0%
Bearish37.5%
Johnson & Johnson · JNJ · FY2026 Q2 · Calendar Q3 2026
JNJ Q2 2026: $25.3B Sales, Guidance Raised to $101.1B Midpoint, New Launches Drive Growth
Johnson & Johnson delivered a solid Q2 2026 with $25.3 billion in sales (5.6% operational growth) and a $400 million raise in full-year guidance to a $101.1 billion midpoint. EPS of $2.90 beat the $2.84 consensus by 2.1%. The quarter was anchored by strong uptake of newly launched products across both Innovative Medicine (ICOTYDE, INLEXZO, RYBREVANT) and MedTech (VARIPULSE, vision lenses), with oncology remaining a primary growth engine through DARZALEX, CARVYKTI, and TALVEY. Despite the beat and raise, shares declined 2.7% on the report session, partially reflecting MedTech cardiovascular headwinds and STELARA biosimilar erosion, before recovering 7.7% over the subsequent period. Management's confident tone and continued pipeline execution (Firefly Bio acquisition, OTTAVA robotics, milvexian readout) reinforce the trajectory toward double-digit growth by decade's end.
Reported Before market openNYSEHealthcare
$640.20B market cap
100quality score
Company context
Snapshot as of publicationJohnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Earnings scorecard
Reported versus consensus
Reported EPS
$2.90
Consensus $3
EPS surprise
+2.1%
Reported versus consensus
Reported revenue
$25.31B
Consensus $25.06B
Revenue surprise
+1.0%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$265.95Previous close
$90Low
$218.61Average
$305High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 28, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Guggenheim | Buy | Buy | Maintain | Jul 17, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 16, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 16, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Jul 16, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 16, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 13, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jul 10, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 8, 2026 |
| Leerink Partners | Outperform | Market Perform | Upgrade | May 13, 2026 |
| Stifel | Hold | Hold | Maintain | Apr 15, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Apr 15, 2026 |
| HSBC | Buy | Buy | Maintain | Mar 17, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Mar 5, 2026 |
| Freedom Capital Markets | Hold | Hold | Maintain | Jan 27, 2026 |
| Freedom Broker | Hold | Hold | Maintain | Jan 27, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Jan 22, 2026 |
| Bernstein | Market Perform | Market Perform | Maintain | Jan 9, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Dec 19, 2025 |
| UBS | Buy | Buy | Maintain | Oct 14, 2025 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Oct 16, 2024 |
| Daiwa Capital | Neutral | Outperform | Downgrade | Jul 23, 2024 |
| Atlantic Equities | Neutral | Neutral | Maintain | Aug 4, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Jul 21, 2023 |
| Mizuho | Buy | Buy | Maintain | Jun 7, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 20, 2023 |
| Independent Research | Buy | Hold | Upgrade | Jul 20, 2020 |
| Argus Research | Buy | Buy | Maintain | Mar 27, 2020 |
| BMO Capital | Outperform | Outperform | Maintain | Apr 17, 2019 |
| Argus | Buy | Buy | Maintain | May 5, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 18, 2018 |
| Jefferies | Buy | Hold | Upgrade | Oct 11, 2017 |
| BTIG Research | Sell | Neutral | Downgrade | Jul 21, 2017 |
| BTIG | Sell | Neutral | Downgrade | Jul 21, 2017 |
| Standpoint Research | Sell | Sell | Maintain | May 20, 2016 |
| Societe Generale | Hold | Hold | Maintain | Apr 6, 2016 |
| Deutsche Bank | Buy | Buy | Maintain | Feb 4, 2016 |
| Bank of America | Neutral | Neutral | Maintain | Apr 16, 2014 |
| Davenport | Hold | Neutral | Maintain | Dec 10, 2012 |
| PiperJaffray | Neutral | Neutral | Maintain | Jul 18, 2012 |
| Piper Sandler | Neutral | Neutral | Maintain | Jul 18, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $265.95. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Johnson Rice | Ilya Zubkov | $280 | $249.76 | +5.3% | Jul 16, 2026 |
| Scotiabank | Analyst unavailable | $305 | $248.95 | +14.7% | Jul 16, 2026 |
| Raymond James | Analyst unavailable | $265 | $250.5 | -0.4% | Jul 16, 2026 |
| Johnson Rice | Analyst unavailable | $261 | $250.49 | -1.9% | Jul 16, 2026 |
| Goldman Sachs | Analyst unavailable | $282 | $247.02 | +6.0% | Jul 16, 2026 |
| Morgan Stanley | Terence Flynn | $294 | $247.02 | +10.5% | Jul 16, 2026 |
| Wells Fargo | Analyst unavailable | $272 | $247.02 | +2.3% | Jul 16, 2026 |
| Stifel Nicolaus | Rick Wise | $260 | $247.02 | -2.2% | Jul 15, 2026 |
| RBC Capital | Analyst unavailable | $287 | $257.6 | +7.9% | Jul 13, 2026 |
| Morgan Stanley | Terence Flynn | $284 | $267.24 | +6.8% | Jul 8, 2026 |
| HSBC | Analyst unavailable | $290 | $258.66 | +9.0% | Jul 6, 2026 |
| Guggenheim | Vamil Divan | $270 | $253.56 | +1.5% | Jun 26, 2026 |
| Johnson Rice | Analyst unavailable | $270 | $253.29 | +1.5% | Jun 26, 2026 |
| Leerink Partners | David Risinger | $265 | $224.26 | -0.4% | May 13, 2026 |
| Guggenheim | Analyst unavailable | $266 | $232.71 | +0.0% | Apr 20, 2026 |
| Morgan Stanley | Analyst unavailable | $283 | $239.66 | +6.4% | Apr 15, 2026 |
| RBC Capital | Analyst unavailable | $265 | $240.1 | -0.4% | Apr 15, 2026 |
| Stifel Nicolaus | Rick Wise | $250 | $240.1 | -6.0% | Apr 15, 2026 |
| Barclays | Matt Miksic | $255 | $240.1 | -4.1% | Apr 15, 2026 |
| Morgan Stanley | Analyst unavailable | $267 | $239.5 | +0.4% | Apr 10, 2026 |
| Morgan Stanley | Analyst unavailable | $253 | $237.19 | -4.9% | Mar 18, 2026 |
| RBC Capital | Analyst unavailable | $255 | $233.35 | -4.1% | Feb 3, 2026 |
| Morgan Stanley | Terrance Flynn | $262 | $224.44 | -1.5% | Jan 28, 2026 |
| Loop Capital Markets | Ilya Zubkov | $220 | $225.16 | -17.3% | Jan 27, 2026 |
| Guggenheim | Vamil Divan | $240 | $218.49 | -9.8% | Jan 23, 2026 |
| Scotiabank | Analyst unavailable | $265 | $220.18 | -0.4% | Jan 22, 2026 |
| Morgan Stanley | Terence Flynn | $200 | $220.37 | -24.8% | Jan 22, 2026 |
| Stifel Nicolaus | Rick Wise | $220 | $218.01 | -17.3% | Jan 22, 2026 |
| Goldman Sachs | Asad Haider | $250 | $218.01 | -6.0% | Jan 22, 2026 |
| Wells Fargo | Analyst unavailable | $240 | $218.01 | -9.8% | Jan 22, 2026 |
| Bernstein | Lee Hambright | $208 | $205.75 | -21.8% | Jan 9, 2026 |
| Barclays | Matt Miksic | $217 | $207.56 | -18.4% | Dec 30, 2025 |
| Goldman Sachs | Asad Haider | $240 | $210.33 | -9.8% | Dec 18, 2025 |
| RBC Capital | Analyst unavailable | $240 | $209.08 | -9.8% | Dec 17, 2025 |
| Morgan Stanley | Analyst unavailable | $197 | $210.6 | -25.9% | Dec 12, 2025 |
| RBC Capital | Analyst unavailable | $230 | $206.54 | -13.5% | Dec 11, 2025 |
| HSBC | Analyst unavailable | $240 | $199.96 | -9.8% | Dec 10, 2025 |
| Guggenheim | Analyst unavailable | $227 | $202.48 | -14.6% | Dec 5, 2025 |
| Barclays | Analyst unavailable | $197 | $205.34 | -25.9% | Dec 2, 2025 |
| Johnson Rice | Ilya Zubkov | $190 | $193.18 | -28.6% | Oct 22, 2025 |
| Loop Capital Markets | Ilya Zubkov | $190 | $193.18 | -28.6% | Oct 22, 2025 |
| Argus Research | David Toung | $210 | $191.19 | -21.0% | Oct 15, 2025 |
| Raymond James | Analyst unavailable | $209 | $190.85 | -21.4% | Oct 15, 2025 |
| Morgan Stanley | Terence Flynn | $190 | $190.85 | -28.6% | Oct 15, 2025 |
| Stifel Nicolaus | Analyst unavailable | $190 | $190.85 | -28.6% | Oct 15, 2025 |
| UBS | Analyst unavailable | $214 | $187.22 | -19.5% | Oct 14, 2025 |
| RBC Capital | Shagun Singh | $209 | $191.3 | -21.4% | Oct 10, 2025 |
| Bernstein | Analyst unavailable | $193 | $188.64 | -27.4% | Oct 6, 2025 |
| UBS | Analyst unavailable | $198 | $185.98 | -25.5% | Oct 3, 2025 |
| Wells Fargo | Larry Biegelsen | $212 | $185.98 | -20.3% | Oct 3, 2025 |
| Raymond James | Jayson Bedford | $162 | $154.36 | -39.1% | Apr 14, 2025 |
| Guggenheim | Vamil Divan | $166 | $151.87 | -37.6% | Feb 3, 2025 |
| Goldman Sachs | Chris Shibutani | $159 | $164.28 | -40.2% | Oct 16, 2024 |
| Morgan Stanley | Terence Flynn | $175 | $164.1 | -34.2% | Oct 16, 2024 |
| RBC Capital | Shagun Singh | $181 | $164.1 | -31.9% | Oct 16, 2024 |
| Citigroup | Joanne Wuensch | $185 | $164.1 | -30.4% | Oct 16, 2024 |
| Wells Fargo | Larry Biegelsen | $166 | $164.1 | -37.6% | Oct 15, 2024 |
| Stifel Nicolaus | Rick Wise | $170 | $164.1 | -36.1% | Oct 15, 2024 |
| Citigroup | Joanna Wuensch | $180 | $163.77 | -32.3% | Oct 15, 2024 |
| Cantor Fitzgerald | Louise Chen | $215 | $161.6 | -19.2% | Oct 14, 2024 |
| Johnson Rice | Narumi Nakagiri | $150 | $154.24 | -43.6% | Jul 23, 2024 |
| Stifel Nicolaus | Rick Wise | $160 | $157.16 | -39.8% | Jul 17, 2024 |
| Johnson Rice | Chris Shibutani | $160 | $144.44 | -39.8% | May 30, 2024 |
| Goldman Sachs | Chris Shibutani | $160 | $144.42 | -39.8% | May 30, 2024 |
| UBS | Danielle Antalffy | $180 | $152.34 | -32.3% | May 22, 2024 |
| Johnson Rice | Morten Herholdt | $170 | $145.08 | -36.1% | Apr 18, 2024 |
| Johnson Rice | Louise Chen | $215 | $144.32 | -19.2% | Apr 17, 2024 |
| RBC Capital | Shagun Singh | $175 | $144.45 | -34.2% | Apr 17, 2024 |
| Stifel Nicolaus | Rick Wise | $155 | $144.45 | -41.7% | Apr 16, 2024 |
| Morgan Stanley | Terence Flynn | $169 | $155.77 | -36.5% | Mar 27, 2024 |
| Wells Fargo | Larry Biegelsen | $163 | $156.35 | -38.7% | Dec 28, 2023 |
| Johnson Rice | Shagun Singh | $178 | $157.24 | -33.1% | Oct 5, 2023 |
| Johnson Rice | Trung Huynh | $175 | $170.45 | -34.2% | Jul 21, 2023 |
| Raymond James | John Ransom | $90 | $156.6 | -66.2% | May 24, 2023 |
| Citigroup | Analyst unavailable | $205 | $176.17 | -22.9% | Dec 12, 2022 |
| Morgan Stanley | Analyst unavailable | $176 | $178.79 | -33.8% | Dec 6, 2022 |
| Morgan Stanley | Analyst unavailable | $178 | $178.49 | -33.1% | Dec 1, 2022 |
| UBS | Analyst unavailable | $180 | $170.71 | -32.3% | Jul 21, 2022 |
| Wells Fargo | Larry Biegelsen | $195 | $170.71 | -26.7% | Jul 20, 2022 |
| Leerink Partners | Analyst unavailable | $194 | $170.86 | -27.1% | Jul 20, 2022 |
| Raymond James | Analyst unavailable | $192 | $171.69 | -27.8% | Jul 20, 2022 |
| Citigroup | Analyst unavailable | $201 | $171.69 | -24.4% | Jul 20, 2022 |
| Morgan Stanley | Analyst unavailable | $174 | $178.5 | -34.6% | Jul 8, 2022 |
| Citigroup | Analyst unavailable | $210 | $183.51 | -21.0% | Apr 20, 2022 |
| Raymond James | Analyst unavailable | $196 | $183.46 | -26.3% | Apr 20, 2022 |
| Credit Suisse | Analyst unavailable | $205 | $182.64 | -22.9% | Apr 20, 2022 |
| Raymond James | Jayson Bedford | $195 | $177.66 | -26.7% | Apr 18, 2022 |
| Morgan Stanley | Matthew Harrison | $173 | $179.84 | -35.0% | Apr 11, 2022 |
| Societe Generale | Florent Cespedes | $177 | $171.79 | -33.4% | Jan 28, 2022 |
| Goldman Sachs | Chris Shibutani | $163 | $168.38 | -38.7% | Jan 26, 2022 |
| Credit Suisse | Matt Miksic | $200 | $170.46 | -24.8% | Dec 29, 2021 |
| UBS | Kevin Caliendo | $183 | $166.8 | -31.2% | Jul 22, 2021 |
| Argus Research | David Toung | $190 | $166.8 | -28.6% | Jul 22, 2021 |
Track every rating change on JNJ the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
-2.7%
Event window
SPY move
+0.4%
Same window
Abnormal move
-3.1%
Stock minus SPY
Volume
1.2×
Versus trailing sessions
Subsequent drift
+7.7%
Up to 20 sessions
JNJSPY benchmark
Follow JNJ with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Compared to Q1 2026, where operational sales grew 6.4% and full-year guidance was raised to a $100.2-$100.8B midpoint, Q2 decelerated slightly to 5.6% operational growth but the guidance raise was larger, up $400M to a $101.1B midpoint with an operational growth target of 6.5-7.1%. Key new developments this quarter include the planned Firefly Bio acquisition adding a KRAS-targeted antibody platform, advancement of the OTTAVA robotic surgical system toward FDA authorization, and progress on the milvexian anticoagulant program with an AFib study readout expected later in 2026. MedTech cardiovascular faced short-term headwinds, while vision, surgery, and orthopedics showed acceleration. STELARA biosimilar competition continued to erode that franchise, though new immunology launches are offsetting the decline.
Guidance delta
Full-year 2026 sales guidance raised by $400 million to a midpoint of $101.1 billion, with an operational growth target of 6.5-7.1%. In Q1, guidance had been raised to a $100.2-$100.8B midpoint. This marks the second consecutive quarterly guidance raise for FY2026. Guidance sentiment: raised.
Key takeaways
- Q2 2026 operational sales grew 5.6% YoY to $25.3B, with EPS of $2.90 beating consensus by 2.1%.
- Full-year 2026 sales guidance raised $400M to a $101.1B midpoint, the second consecutive quarterly raise.
- New product launches including ICOTYDE, INLEXZO, RYBREVANT, and VARIPULSE are delivering strong early uptake across Innovative Medicine and MedTech.
- Oncology remains a core growth engine, with DARZALEX, CARVYKTI, and TALVEY posting high double-digit growth.
- MedTech cardiovascular faced short-term headwinds, but vision, surgery, and orthopedics accelerated.
Management priorities
- Close Firefly Bio acquisition in Q3 2026 to add a KRAS-targeted antibody platform to the oncology pipeline.
- Seek FDA approval and commercial launch of OTTAVA robotic surgical system and MONARCH urology robot.
- Launch dual-energy THERMOCOOL SMARTTOUCH SF platform and Shockwave C2 Aero catheters.
- Advance pipeline data readouts for IMAAVY, TECVAYLI/TALVEY combinations, pasritamig, and J&J 6143.
- Expand TECNIS PureSee intra-ocular lens availability and ACUVUE OASYS MAX lens portfolio.
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-07-16T09:03:14.807849+00:00
- FN2 earnings calendar · 2026-07-28T01:23:15.070317+00:00
- Polygon adjusted daily market bars · 2026-07-28T06:51:30.016180+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T06:51:30.013687+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.